Glucose homeostasis and the gastrointestinal tract: Insights into the treatment of diabetes

Diabetes, Obesity and Metabolism

Volumn 10, Issue 1, 2008, Pages 18-33

  Maggs, David ^a   Macdonald, I ^b   Nauck, M A ^c  

^a AMYLIN PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c Diabeteszentrum   (Germany)

Author keywords

Diabetes; Gastric emptying; Gastroparesis; Gut hormones

Indexed keywords

ACARBOSE; AMYLIN DERIVATIVE; CHOLECYSTOKININ; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ERYTHROMYCIN; EXENDIN 4; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; INSULIN LISPRO; LIRAGLUTIDE; METFORMIN; MORPHINE; PARACETAMOL; PLACEBO; PRAMLINTIDE; SULFONYLUREA; TETRAHYDROLIPSTATIN;

ADJUVANT THERAPY; CLINICAL TRIAL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL TOXICITY; GASTROINTESTINAL TRACT FUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HORMONAL REGULATION; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESPONSE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUTRIENT CONTENT; OBESITY; PATHOPHYSIOLOGY; POSTPRANDIAL STATE; REVIEW; SINGLE DRUG DOSE; STOMACH EMPTYING; STOMACH PARESIS;

EID: 37349087240     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2007.00737.x     Document Type: Review

References (186)

1. Aronoff SL, Berkowitz K, Schreiner B, Want L. Glucose metabolism and regulation: Beyond insulin and glucagon. Diabetes Spectr 2004; 17: 183-190.
2. Kelley D, Mitrakou A, Marsh H et al. Skeletal muscle glycolysis, oxidation, and storage of an oral glucose load. J Clin Invest 1988; 81: 1563-1571.
3. Unger RH, Dobbs RE, Orci L. Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Annu Rev Physiol 1978; 40: 307-343.
4. Pehling G, Tessari P, Gerich JE, Haymond MW, Service FJ, Rizza RA. Abnormal meal carbohydrate disposition in insulin-dependent diabetes. Relative contributions of endogenous glucose production and initial splanchnic uptake and effect of intensive insulin therapy. J Clin Invest 1984; 74: 985-991.
5. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284: E671-E678.
6. Young A. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diab 1997; 4: 282-290.
7. Sachs G, Zeng N, Prinz C. Physiology of isolated gastric endocrine cells. Ann Rev Physiol 1997; 59: 243-256.
8. Holst JJ. Glucagon-like peptide 1 (GLP-1). An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol Metab 1999; 10: 229-235.
9. Meier JJ, Nauck MA, Schmidt WE, Gallwitz B. Gastric inhibitory polypeptide: The neglected incretin revisited. Regul Pept 2002; 107: 1-13.
10. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: Studies in normal and diabetic subjects. J Clin Invest 1967; 46: 1954-1962.
11. Nauck MA, Homberger E, Siegel EG et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab 1986; 63: 492-498.
12. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206.
13. Drucker DJ, Nauck MA. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006; 368: 1696-1705.
14. Orskov C, Wettergren A, Holst JJ. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 1993; 42: 658-661.
15. Drucker DJ. Related articles, links enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26: 2929-2940.
16. Schirra J, Sturm K, Leicht P, Arnold R, Goke B, Katschinski M. Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. J Clin Invest 1998; 101: 1421-1430.
17. Schirra J, Nicolaus M, Roggel R et al. Endogenous glucagon-like peptide 1 controls endocrine pancreatic secretion and antro-pyloro-duodenal motility in humans. Gut 2006; 55: 243-251.
18. Nielsen LL. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 2005; 10: 703-710.
19. Corvilain B, Abramowicz M, Fery F et al. Effect of short-term starvation on gastric emptying in humans: Relationship to oral glucose tolerance. Am J Physiol 1995; 269: G512-G517.
20. Horowitz M, Edelbroek MA, Wishart JM, Straathof JW. Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects. Diabetologia 1993; 36: 857-862.
21. Ishii M, Nakamura T, Kasai F, Onuma T, Baba T, Takebe K. Altered postprandial insulin requirement in IDDM patients with gastroparesis. Diabetes Care 1994; 17: 901-903.
22. Jones KL, Horowitz M, Carney BI, Wishart JM, Guha S, Green L. Gastric emptying in early noninsulin-dependent diabetes mellitus. J Nucl Med 1996; 37: 1643-1648.
23. Blair EH, Wing RR, Wald A. The effect of laboratory stressors on glycemic control and gastrointestinal transit time. Psychosom Med 1991; 53: 133-143.
24. Mourot J, Thouvenot P, Couet C, Antoine JM, Krobicka A, Debry G. Relationship between the rate of gastric emptying and glucose and insulin responses to starchy foods in young healthy adults. Am J Clin Nutr 1988; 48: 1035-1040.
25. Horowitz M, Wishart JM, Jones KL, Hebbard GS. Gastric emptying in diabetes: An overview. Diabet Med 1996; 13: S16-S22.
26. Schwartz JG, Green GM, Guan D, McMahan CS, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996; 19: 468-471.
27. Shultz KT, Neelon FA, Nilsen LB, Lebovitz HE. Mechanism of postgastrectomy hypoglycaemia. Arch Intern Med 1971; 128: 240-246.
28. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001; 24: 371-381.
29. Hunt JN, Knox MT. Control of gastric emptying. Am J Dig Dis 1968; 13: 372-375.
30. Horowitz M, Dent J, Fraser R, Sun W, Hebbard G. Role and integration of mechanisms controlling gastric emptying. Dig Dis Sci 1994; 39: 7S-13S.
31. Horowitz M, Fraser R. Disordered gastric motor function in diabetes mellitus. Diabetologia 1994; 37: 543-551.
32. Horowitz M, Dent J. Disordered gastric emptying: Mechanical basis, assessment and treatment. Baillieres Clin Gastroenterol 1991; 5: 371-407.
33. Vist GE, Maughan RJ. The effect of osmolality and carbohydrate content on the rate of gastric emptying of liquids in man. J Physiol 1995; 486: 523-531.
34. Lin HC, Doty JE, Reedy TJ, Meyer JH. Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient. Am J Physiol 1989; 256: G404-G411.
35. Lin HC, Doty JE, Reedy TJ, Meyer JH. Inhibition of gastric emptying by acids depends on pH, titratable acidity, and length of intestine exposed to acid. Am J Physiol 1990; 259: G1025-G1030.
36. Lin HC, Doty JE, Reedy TJ, Meyer JH. Inhibition of gastric emptying by sodium oleate depends on length of intestine exposed to nutrient. Am J Physiol 1990; 259: G1030-G1036.
37. Heddle R, Fone D, Dent J, Horowitz M. Stimulation of pyloric motility by intraduodenal dextrose in normal subjects. Gut 1988; 29: 1349-1357.
38. Fone DR, Horowitz M, Dent J, Read NW, Heddle R. Pyloric motor response to intraduodenal dextrose involves muscarinic mechanisms. Gastroenterology 1989; 97: 83-90.
39. Edelbroek M, Horowitz M, Dent J et al. Effects of duodenal distention on fasting and postprandial antropyloroduodenal motility in humans. Gastroenterology 1994; 106: 583-592.
40. Edelbroek M, Horowitz M, Fraser R et al. Adaptive changes in the pyloric motor response to intraduodenal dextrose in normal subjects. Gastroenterology 1992; 103: 1754-1761.
41. Heddle R, Collins PJ, Dent J et al. Motor mechanisms associated with slowing of the gastric emptying of a solid meal by an intraduodenal lipid infusion. J Gastroenterol Hepatol 1989; 4: 437-447.
42. Cunningham KM, Daly J, Horowitz M, Read NW. Gastrointestinal adaptation to diets of differing fat composition in human volunteers. Gut 1991; 32: 483-486.
43. Barnett JL, Owyang C. Serum glucose concentration as a modulator of interdigestive gastric motility. Gastroenterology 1988; 94: 739-744.
44. Schvarcz E, Palmer M, Aman J, Horowitz M, Stridsberg M, Berne C. Physiological hyperglycemia slows gastric emptying in normal subjects and patients with insulin-dependent diabetes mellitus. Gastroenterology 1997; 113: 60-66.
45. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 675-680.
46. Horowitz M, Harding PE, Maddox AF et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989; 32: 151-159.
47. MacGregor IL, Gueller R, Watts HD, Meyer JH. The effect of acute hyperglycemia on gastric emptying in man. Gastroenterology 1976; 70: 190-196.
48. Samsom M, Akkermans LM, Jebbink RJ et al. Gastrointestinal motor mechanisms in hyperglycaemia induced delayed gastric emptying in type I diabetes mellitus. Gut 1997; 40: 641-646.
49. Russo A, Stevens JE, Chen R et al. Insulin-induced hypoglycemia accelerates gastric emptying of solids and liquids in long-standing type 1 diabetes. J Clin Endocrinol Metab 2005; 90: 4489-4495.
50. Schvarcz E, Palmer M, Aman J, Lindkvist B, Beckman KW. Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus. Diabet Med 1993; 10: 660-663.
51. Schvarcz E, Palmer M, Aman J, Berne C. Hypoglycemia increases the gastric emptying rate in healthy subjects. Diabetes Care 1995; 18: 674-676.
52. Quigley J, Johnson V, Solomon E. Action of insulin on the motility of the gastrointestinal tract I. Action on the stomach of normal fasting man. Am J Physiol 1929; 90: 89-98.
53. Heinz T, Palmer W. A study of the effect of insulin on gastric motility. Proc Soc Exp Biol Med 1930; 27: 1047-1049.
54. Quigley J, Templeton R. Action of insulin on the motility of the gastrointestinal tract III. a. Action on the pyloric pouch. b. Action on the stomach following double splanchnicotomy. Am J Physiol 1930; 91: 475-481.
55. Quigley J, Templeton R. Action of insulin on the motility of the gastrointestinal tract IV. Action on the stomach following double vagotomy. Am J Physiol 1930; 91: 482-487.
56. Wilder R, Schultz F. The action of atropine and adrenaline on gastric tonus and hypermotility induced by insulin hypoglycaemia. Am J Physiol 1931; 96: 54-58.
57. Lalkich J, Youmans W, Meek W. Insulin and gastric motility. Am J Physiol 1937; 120: 554-558.
58. Eliasson B, Bjornsson E, Urbanavicius V et al. Hyperinsulinaemia impairs gastrointestinal motility and slows carbohydrate absorption. Diabetologia 1995; 38: 79-85.
59. Hasler WL, Soudah HC, Dulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995; 108: 727-736.
60. Kong MF, King P, Macdonald IA et al. Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects. Diabetologia 1998; 41: 474-481.
61. Kong MF, King P, MacDonald IA et al. Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus. Diabetologia 1999; 42: 365-372.
62. Gielkens HA, Verkijk M, Frolich M, Lamers CB, Masclee AA. Is the effect of acute hyperglycaemia on interdigestive antroduodenal motility and small-bowel transit mediated by insulin? Eur J Clin Invest 1997; 27: 703-710.
63. Schjoldager B, Lawaetz O, Christiansen J. Effect of pancreatic glucagon and its 1-21 fragment on gastric emptying in man. Scand J Gastroenterol 1988; 23: 726-730.
64. Patel GK, Whalen GE, Soergel KH, Wu WC, Meade RC. Glucagon effects on the human small intestine. Dig Dis Sci 1979; 24: 501-508.
65. Katsuura G, Asakawa A, Inue A. Roles of pancreatic polypeptide in regulation of food intake. Peptides 2002; 23: 323-329.
66. Ogawa A, Harris V, McCorkle SK, Unger RH, Luskey KL. Amylin secretion from the rat pancreas and its selective loss after streptozotocin treatment. J Clin Invest 1990; 85: 973-976.
67. Moore CX, Cooper GJ. Co-secretion of amylin and insulin from cultured islet beta-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents. Biochem Biophys Res Commun 1991; 179: 1-9.
68. Koda JE, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. Amylin concentrations and glucose control. Lancet 1992; 339: 1179-1180.
69. Dilts R, Gedulin B, Jodka C, Beaumont K, Young A. Central infusion of amylin delays gastric emptying in the rat. Pharmacologist 1997; 39: 32.
70. Clementi G, Caruso A, Cutuli VM, de Bernardis E, Prato A, Amico-Roxas M. Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Experientia 1996; 52: 677-679.
71. Jodka C, Green D, Young A, Gedulin B. Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve. Diabetes 1996; 45 (Suppl. 1): 235A.
72. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
73. Dupre J, Behme MT, Hramiak IM et al. Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM. Diabetes 1995; 44: 626-630.
74. Gutniak M, Orskov C, Holst JJ, Ahren JB, Efendic S. Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus. N Engl J Med 1992; 326: 1352-1353.
75. Meier JJ, Goetze O, Anstipp J et al. Gastric inhibitory polypeptide does not inhibit gastric emptying in humans. Am J Physiol Endocrinol Metab 2004; 286: E621-E625.
76. Holst JJ, Orskov C. Incretin hormones-an update. Scand J Clin Lab Invest 2001; 234: 75-85.
77. Liddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986; 77: 992-996.
78. Liddle RA, Rushakoff RJ, Morita ET, Becaria L, Carter JD, Goldfine ID. Physiological role for cholecystokinin in reducing postprandial hyperglycemia in humans. J Clin Invest 1988; 81: 1675-1681.
79. Bloom SR, Ralphs DN, Besser GM et al. Effect of somatostatin on motilin level and gastric emptying. Gut 1975; 16: 834.
80. Schrumpf E. The inhibitory action of somatostatin on the stomach. In: Grossman M, Speranza V, Basso V, Lezoche E eds. Gastrointestinal Hormones and Pathology of the Digestive System. New York: Plenum Press, 1978; 235-240.
81. Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52: 1555-1561.
82. Lamrani A, Vidon N, Sogni P et al. Effects of lanreotide, a somatostatin analogue, on postprandial gastric functions and biliopancreatic secretions in humans. Br J Clin Pharmacol 1997; 43: 65-70.
83. Edelman SV, Weyer C. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: Potential benefit of replacing amylin, a second beta-cell hormone. Diabetes Technol Ther 2002; 4: 175-189.
84. Keshavarzian A, Iber FL, Vaeth J. Gastric emptying in patients with insulin-requiring diabetes mellitus. Am J Gastroenterol 1987; 82: 29-35.
85. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BI, Shearman DJ. Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 1991; 18: 229-234.
86. Lyrenas EB, Olsson EH, Arvidsson UC, Orn TJ, Spjuth JH. Prevalence and determinants of solid and liquid gastric emptying in unstable type I diabetes. Relationship to postprandial blood glucose concentrations. Diabetes Care 1997; 20: 413-418.
87. Wegener M, Borsch G, Schaffstein J, Luerweg C, Leverkus F. Gastrointestinal transit disorders in patients with insulin-treated diabetes mellitus. Dig Dis 1990; 8: 23-36.
88. Ziegler D, Schadewaldt P, Pour Mirza A et al. [13C]Octanoic acid breath test for non-invasive assessment of gastric emptying in diabetic patients: Validation and relationship to gastric symptoms and cardiovascular autonomic function. Diabetologia 1996; 39: 823-830.
89. Nowak TV, Johnson CP, Kalbfleisch JH et al. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995; 37: 23-29.
90. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995; 109: 755-765.
91. Kong MF, Macdonald DI, Tattersall RB. Gastric emptying in diabetes. Diabet Med 1996; 13: 112-119.
92. Abell TL, Bernstein RK, Cutts T et al. Treatment of gastroparesis: A multidisciplinary clinical review. Neurogastroenterol Motil 2006; 18: 263-283.
93. Parkman HP, Hasler WL, Fisher RS. American Gastroenterological Association. American gastroenterological association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592-1622.
94. Rundles RW. Diabetic neuropathy. Bull N Y Acad Med 1950; 26: 598-616.
95. Digestive Disease Interagency Coordinating Committee. Gastroparesis: A common disorder http://www.niddk.nih.gov/federal/ddicc/ minutes_4-2-04.pdf. Accessed 26 April 2007.
96. Schirra J, Katschinski M, Weidmann C et al. Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996; 97: 92-103.
97. Cotroneo P, Grattagliano A, Rapaccini GL et al. Gastric emptying rate and hormonal response in type II diabetics. Diabetes Res 1991; 17: 99-104.
98. Maurer AH, Parkman HP. Update on gastrointestinal scintigraphy. Semin Nucl Med 2006; 36: 110-118.
99. Ajaj W, Goehde SC, Papanikolaou N et al. Real time high resolution magnetic resonance imaging for the assessment of gastric motility disorders. Gut 2004; 53: 1256-1261.
100. French SJ, Read NW. Effect of guar gum on hunger and satiety after meals of differing fat content: Relationship with gastric emptying. Am J Clin Nutr 1994; 59: 87-91.
101. Torsdottir I, Alpsten M, Holm G, Sandberg AS, Tolli J. A small dose of soluble alginate-fiber affects postprandial glycemia and gastric emptying in humans with diabetes. J Nutr 1991; 121: 795-799.
102. Chandalia M, Garg A, Lutjohann D, von Bergmann K, Grundy SM, Brinkley LJ. Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus. N Engl J Med 2000; 342: 1392-1398.
103. Ray TK, Mansell KM, Knight LC, Malmud LS, Owen OE, Boden G. Long-term effects of dietary fiber on glucose tolerance and gastric emptying in noninsulin-dependent diabetic patients. Am J Clin Nutr 1983; 37: 376-381.
104. Gonlachanvit S, Hsu C-W, Boden GH et al. Effect of altering gastric emptying on postprandial plasma glucose concentrations following a physiologic meal in type-II diabetic patients. Dig Dis Sci 2003; 48: 488-497.
105. Janssens J, Peeters TL, Vantrappen G et al. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 1028-1031.
106. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002; 137: 25-33.
107. Forster H, Hager E, Mehnert H. The influence of butylbiguanide in animal experiments on the resorption of glucose and fructose. Arzneimittelforschung 1965; 15: 1340-1344.
108. Vidon N, Chaussade S, Noel M, Franchisseur C, Huchet B, Bernier JJ. Metformin in the digestive tract. Diabetes Res Clin Pract 1988; 4: 223-229.
109. Mannucci E, Ognibene A, Cremasco F et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001; 24: 489-494.
110. Lugari R, Dell'Anna C, Sarti L, Gnudi A. Effects of metformin on intestinal and pancreatic endocrine secretion in type 2 (non-insulin-dependent) diabetes. In:
111. Belfiore F, Lorenzi M, Molinatti GM, Porta M eds. Molecular and Cell Biology of Type 2 Diabetes and its Complications. Basel, Switzerland: Karger, 1998; 161-163.
112. Molloy AM, Ardill J, Tomkin GH. The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects. Diabetologia 1980; 19: 93-96.
113. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24: 720-725.
114. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CHS, Demuth HU. Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302-1308.
115. Hinke SA, Mintosh CHS, Hoffmann T et al. On combination therapy of diabetes with metformin and dipeptidyl IV inhibitors. Diabetes Care 2002; 25: 1490-1491.
116. Deacon CF, Holst JJ. Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes; a historical perspective. Biochem Biophys Res Commun 2002; 294: 1-4.
117. Demuth HU, Hinke SA, Pederson RA, McIntosh CHS. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagons-like peptide-1" versus "dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: A historical perspective."Biochem Biophys Res Commun 2002; 296: 229-232.
118. Caspary WF. Sucrose malabsorption in man after ingestion of alpha-glycosidehydrolase inhibitor. Lancet 1978; 8076: 1231-1233.
119. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14: 732-737.
120. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994; 17: 561-566.
121. Ranganath L, Norris F, Morgan L, Wright J, Marks V. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med 1998; 15: 120-124.
122. Enc FY, Imeryuz N, Akin L et al. Inhibition of gastric emptying by acarbose is correlated with GLP-1 response and accompanied by CCK release. Am J Physiol Gastrointest Liver Physiol 2001; 281: G752-G763.
123. Qualmann C, Nauck MA, Holst JJ, Orskov C, Creutzfeldt W. Glucagon-like peptide 1 (7-36 amide) secretion in response to luminal sucrose from the upper and lower gut. A study using alpha-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30: 892-896.
124. Seifarth C, Bergmann J, Holst JJ, Ritzel R, Schmiegel W, Nauck MA. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients. Diabet Med 1998; 15: 485-491.
125. Juntti-Berggren L, Pigon J, Hellstrom P, Holst JJ, Efendic S. Influence of acarbose on post-prandial insulin requirements in patients with type 1 diabetes. Diabetes Nutr Metab 2000; 13: 7-12.
126. Hucking K, Kostic Z, Pox C et al. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in type 2 diabetic patients. Diabet Med 2005; 22: 470-476.
127. Sternby B, Hartmann D, Borgstrom B, Nilsson A. Degree of in vivo inhibition of human gastric and pancreatic lipases by Orlistat (Tetrahydrolipstatin, THL) in the stomach and small intestine. Clin Nutr 2002; 21: 395-402.
128. Hadvary P, Lengsfeld H, Wolfer H. Inhibition of pancreatic lipase in vitro by the covalent inhibitor tetrahydrolipstatin. Biochem J 1988; 256: 357-361.
129. Porras A, Fernandez M, Benito M. Adrenergic regulation of the uncoupling protein expression in fetal rat brown adipocytes in primary culture. Biochem Biophys Res Commun 1989; 163: 541-547.
130. Hartmann D, Hussain Y, Guzelhan C, Odink J. Effect on dietary fat absorption of orlistat, administered at different times relative to meal intake. Br J Clin Pharmacol 1993; 36: 266-270.
131. Halpern A, Mancini MC, Suplicy H et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obesity Metab 2003; 5: 180-188.
132. Schwizer W, Asal K, Kreiss C et al. Role of lipase in the regulation of upper gastrointestinal function in humans. Am J Physiol 1997; 273: G612-G620.
133. Borovicka J, Schwizer W, Guttmann G et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: A study with orlistat, a highly specific lipase inhibitor. Gut 2000; 46: 774-781.
134. Feinle C, O'Donovan D, Doran S et al. Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans. Am J Physiol Gastrointest Liver Physiol 2002; 284: G798-G807.
135. Wen J, Philllips SF, Sarr MG, Kost LJ, Holst JJ. PYY and GLP-1 contribute to feedback inhibition from the canine ileum and colon. Am J Physiol 1995; 269: G945-G952.
136. MacIntosh CG, Horowitz M, Verhagen MA et al. Effect of small intestinal nutrient infusion on appetite, gastrointestinal hormone release, and gastric myoelectrical activity in young and older men. Am J Gastroenterol 2001; 96: G997-G1007.
137. Feinle C, Chapman IM, Wishart J, Horowitz M. Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men. Peptides 2002; 23: 1491-1495.
138. Pilichiewicz A, O'Donovan D, Feinle C et al. Effect of lipase inhibition on gastric emptying of, and the glycemic and incretin responses to, an oil/aqueous drink in type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 3829-3834.
139. O'Donovan D, Horowitz M, Russo A et al. Effects of lipase inhibition on gastric emptying of, and on the glycaemic, insulin and ardiovascular responses to a high-fat/carbohydrate meal in type 2 diabetes. Diabetologia 2004; 47: 2208-2214.
140. Damci T, Yalin S, Balci H et al. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients. Diabetes Care 2004; 27: 1077-1080.
141. Bretherton-Watt D, Ghatei MA, Legon S, Jamal H, Suda K, Bloom SR. Depletion of islet amyloid polypeptide in the spontaneously diabetic (BB) Wistar rat. J Mol Endocrinol 1991; 6: 3-7.
142. Edelman SV, Darsow T, Frias JP. Pramlintide in the treatment of diabetes. Int J Clin Pract 2006; 60: 1647-1653.
143. Kong MF, King P, Macdonald IA et al. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM. Diabetologia 1997; 40: 82-88.
144. Kong MF, Stubbs TA, King P et al. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM. Diabetologia 1998; 41: 577-583.
145. Samsom M, Szarka LA, Camilleri M, Vella A, Zinsmeister AR, Rizza RA. Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition. Am J Physiol Gastrointest Liver Physiol 2000; 278: G946-G951.
146. Nyholm B, Orskov L, Hove KY et al. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus. Metabolism 1999; 48: 935-941.
147. Fineman MS, Koda JE, Shen LZ et al. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes. Metabolism 2002; 51: 636-641.
148. Fineman M, Weyer C, Maggs DG, Strobel S, Kolterman OG. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34: 504-508.
149. Hollander PA, Levy P, Fineman MS et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial. Diabetes Care 2003; 26: 784-790.
150. Ratner RE, Dickey R, Fineman M. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: A 1-year, randomized controlled trial. Diabet Med 2004; 21: 1204-1212.
151. Whitehouse F, Kruger DF, Fineman M et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002; 25: 724-730.
152. Chapman I, Parker B, Doran S et al. Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005; 48: 838-848.
153. Herrmann-Rinke C, Voge A, Hess M, Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J Endocrinol 1995; 147: 25-31.
154. D'Alessio D, Vahl T, Prigeon R. Effects of glucagon-like peptide 1 on the hepatic glucose metabolism. Horm Metab Res 2004; 36: 837-841.
155. Nauck MA, El-Ouaghlidi A, Gabrys B et al. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regul Pept 2004; 122: 209-217.
156. Schirra J, Houck P, Wank U, Arnold R, Goke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000; 46: 622-631.
157. Flint A, Raben A, Ersboll AK, Holst JJ, Astrup A. The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity. Int J Obes Relat Metab Disord 2001; 25: 781-792.
158. Ritzel R, Orskov C, Holst JJ, Nauck MA. Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 1995; 38: 720-725.
159. D'Alessio DA, Vahl TP. Glucagon-like peptide 1: Evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882-E890.
160. Stoffers DA, Kieffer TJ, Hussain MA et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748.
161. Drucker DJ. Glucagon-like peptide-1 and the islet beta-call: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-5148.
162. Vilsbøll T, Holst JJ. Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004; 47: 357-366.
163. Parkes D, Jodka C, Smith P et al. Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug Dev Res 2001; 53: 260-267.
164. Fineman MS, Bicsak TA, Shen LZ et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26: 2370-2377.
165. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270-2276.
166. Amylin Pharmaceuticals, Inc. BYETTA prescribing information. Available from URL: http://pi.lilly.com/us/byetta-pi.pdf. Accessed 20 April 2006.
167. Kolterman OG, Buse JB, Fineman MS et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 3082-3089.
168. Kolterman OG, Kim DD, Shen L et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005; 62: 173-181.
169. Buse JB, Henry RR, Han J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2628-2635.
170. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005; 28: 1092-1100.
171. Kendall DM, Riddle MC, Rosenstock J et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005; 28: 1083-1091.
172. Edwards CM, Stanley SA, Davis R et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol Endocrinol Metab 2001; 281: E155-E161.
173. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195-202.
174. Elbrond B, Jakobsen G, Larsen S et al. Pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25: 1398-1404.
175. Juhl CB, Hollingdal M, Sturis J et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 2002; 51: 424-429.
176. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. NN2211-1310 International Study Group. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27: 1335-1342.
177. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a
178. Nauck MA, Hompesch M, Filipczak R et al. Liraglutide significantly improves glycemic control and reduces body weight compared with glimepiride as add-on to metformin in type 2 diabetes. Diabetes 2004; 53: A356.
179. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89: 2078-2084.
180. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9-24.
181. Pratley R, Galbreath E. Twelve-week monotherapy with the DPP-4 inhibitor, LAF237 improves glycemic control in patients with type 2 diabetes (T2DM). Diabetes 2004; 53: A83.
182. Ahren B, Gomis R, Mills D, Schweizer A. The DPP-4 inhibitor, LAF237, improves glycemic control in patients with type 2 diabetes (T2DM) inadequately treated with metformin. Diabetes 2004; 53: A83.
183. Ahren B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004; 27: 2874-2880.
184. Ahren B, Simonsson E, Larsson H et al. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002; 25: 869-875.
185. Christofides ND, Long RG, Fitzpatrick ML, McGregor GP, Bloom SR. Effect of motilin on the gastric emptying of glucose and fat in humans. Gastroenterology 1981; 80: 456-460.
186. Feldman M, Walsh JH, Taylor IL. Effect of naloxone and morphine on gastric acid secretion and on serum gastrin and pancreatic polypeptide concentrations in humans. Gastroenterology 1980; 79: 294-298.